News >

Bypassing Endocrine Resistance in Advanced HR+ Breast Cancer

Caroline Seymour
Published: Tuesday, Jun 25, 2019

Christopher R. Chitambar, MD, FACP

Christopher R. Chitambar, MD, FACP

Treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer depended on blocking the estrogen receptor (ER), until research showed that cancer proliferation was possible independent of the ER, explained Christopher R. Chitambar, MD, FACP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication